Beyond Invisible: Confronting the Policy and Practice Void in Eating Disorder Prevention and Treatment for Indigenous Peoples in Canada
Abstract
Indigenous populations internationally experience eating disorders (EDs) at similar or higher rates than colonizing majority populations. In Canada, emerging evidence suggests that this is also true among First Nations, Métis, and Inuit (FNMI) populations. However, most existing recommendations and best practices for ED prevention, early intervention, and treatment do not consider unique contextual and cultural factors that are relevant to FNMI Peoples, such as the effects of historical and ongoing colonialism. This scoping review aimed to map policy-related documents on the prevention, early intervention, and treatment of EDs among FNMI Peoples. We searched academic databases and targeted websites for ED policies, reports, toolkits, guidelines, and fact sheets. Targeted searches included the websites of Indigenous health authorities (e.g., National Collaborating Centre for Indigenous Health) and community websites, ED-specific organizations (e.g., National Eating Disorder Information Centre), and health professional associations (e.g., Canadian Psychological Association). We found only two relevant documents: one commentary serving as a call to action and one education resource for people experiencing EDs or disordered eating and their family members. Both documents were led by Indigenous authors with lived experience of EDs and were published by the National Eating Disorder Information Centre. In the absence of wider guidance on prevention, early intervention, and…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.